Los Angeles Capital Management LLC Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Los Angeles Capital Management LLC bought a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,606 shares of the specialty pharmaceutical company's stock, valued at approximately $625,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Crossmark Global Holdings Inc. lifted its position in shares of Jazz Pharmaceuticals by 23.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company's stock valued at $567,000 after acquiring an additional 970 shares in the last quarter. CWA Asset Management Group LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter worth $3,197,000. Philip James Wealth Mangement LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth $830,000. AlphaCentric Advisors LLC boosted its position in Jazz Pharmaceuticals by 40.9% during the third quarter. AlphaCentric Advisors LLC now owns 15,500 shares of the specialty pharmaceutical company's stock valued at $1,727,000 after purchasing an additional 4,500 shares during the last quarter. Finally, Van ECK Associates Corp grew its stake in Jazz Pharmaceuticals by 11.4% in the third quarter. Van ECK Associates Corp now owns 60,211 shares of the specialty pharmaceutical company's stock valued at $6,691,000 after purchasing an additional 6,157 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ traded down $2.62 during trading hours on Friday, hitting $121.65. 718,165 shares of the company traded hands, compared to its average volume of 637,015. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of 17.13, a P/E/G ratio of 1.02 and a beta of 0.57. The firm has a 50-day moving average of $112.22 and a 200 day moving average of $110.35. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JAZZ. Piper Sandler reduced their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating for the company in a report on Thursday, August 1st. Robert W. Baird dropped their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research note on Thursday, August 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, November 7th. Royal Bank of Canada increased their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 23rd. Finally, StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $175.00.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,110 shares of company stock valued at $720,160. 4.20% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.